Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NISCH | Q9Y2I1 | 9/20 | 0.49 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | MAOB | P27338 | 1/20 | 0.37 |
| ▸ | TOP2A | P11388 | 2/20 | 0.36 |
| ▸ | TOP2B | Q02880 | 2/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4819234 | 0.84 | NISCH (0.44) | NISCHGAATSHRMAOBTOP2A | |
| SCHEMBL4824349 | 0.81 | MAOB (0.48) | NISCHGAATSHRMAOBTOP2A | |
| SCHEMBL4357405 | 0.80 | MAOB (0.39) | NISCHGAATSHRMAOB | |
| Hydrochloric Acid SCHEMBL4912426 | 0.80 | NISCH (0.48) | NISCHGAATSHRMAOBTOP2A | |
| Hydrochloric Acid SCHEMBL4910323 | 0.78 | NISCH (0.46) | NISCHGAATSHRTOP2ATOP2B | |
| SCHEMBL4362775 | 0.76 | NISCH (0.43) | NISCHGAATSHRTOP2ATOP2B | |
| Hydrochloric Acid SCHEMBL4910922 | 0.75 | NISCH (0.43) | NISCHGAATSHRTOP2ATOP2B | |
| Hydrochloric Acid SCHEMBL4914061 | 0.74 | MC4R (0.46) | NISCHGAATSHRMAOB | |
| SCHEMBL4820152 | 0.73 | ALDH1A1 (0.49) | NISCHGAATSHR | |
| SCHEMBL4298620 | 0.72 | NISCH (0.58) | NISCHGAATSHRTOP2ATOP2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080269217-A1 | Melanocortin-4 receptor binding compounds and methods of use thereof | ORE PHARMACEUTICALS, INC. (US) | 2008-10-30 | — | — | US | disclosed |
| US-7375125-B2 | Melanocortin-4 receptor binding compounds and methods of use thereof | ORE PHARMACEUTICALS, INC. (US) | 2008-05-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080269217-A1 | Melanocortin-4 receptor binding compounds and methods of use thereof | MC4R, MC5R, MC3R | NISCH 1934/4885GAA 2982/4885TSHR 47/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.